Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in Unresectable Hepatocellular Carcinoma

NCT05864105 is registered in ClinicalTrials.gov with Biotheus Inc. as lead sponsor.

NCT NCT05864105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05864105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in Unresectable Hepatocellular Carcinoma
Lead sponsor
Biotheus Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 22, 2022
Completion date
July 24, 2025
Enrollment
35 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma